Dense Breasts and Breast Cancer Risk

What is breast density?

Breast tissue is a mixture of fat, glandular tissue (milk-producing) and fibrous connective tissue. Breast density measures how much of the breast is glandular and fibrous compared to fatty tissue. On a mammogram X-ray, glandular and fibrous tissue appear white, as do potential tumours — while fat appears dark. This overlap is the core challenge of dense tissue.

BI-RADS density categories

Radiologists use the BI-RADS (Breast Imaging Reporting and Data System) classification:

• Category A — Almost entirely fatty: less than 25% glandular tissue. Easiest for mammography to read.
• Category B — Scattered fibroglandular density: 25–50% glandular tissue.
• Category C — Heterogeneously dense: 51–75% glandular tissue. Most common in women of screening age.
• Category D — Extremely dense: over 75% glandular tissue. Most challenging for mammography.

Around 40% of women of mammography screening age fall into Category C or D — what is commonly referred to as "dense breasts." Density tends to decrease with age but varies significantly between individuals. It is not something you can feel or notice yourself.

Why dense breasts matter: two separate risks

• Masking effect: dense tissue and potential tumours both appear white on mammogram X-ray, making cancers harder to spot. Mammogram sensitivity can be reduced by 30–40% in extremely dense breasts. Cancers in dense tissue are significantly more likely to be "interval cancers" — found due to symptoms between screening rounds rather than at the screening itself.
• Independent cancer risk: dense breast tissue itself raises breast cancer risk by approximately 1.6–2 times, independent of the masking effect. This is thought to relate to the higher proportion of dividing glandular cells in which mutations can occur.

The US FDA rule change: September 2024

Effective September 10, 2024, the US Food and Drug Administration (FDA) requires all mammography facilities to include breast density information in written patient notification letters. Every woman in the US who has a mammogram now receives a written statement indicating whether she has dense breasts and what this means for her screening. Before this rule, many women were never informed of their density despite its clinical importance.

The UK position

In the UK, there is currently no mandatory requirement to notify women of their breast density following an NHS mammogram. Radiologists take density into account when reading mammograms, and women with extremely dense tissue may receive supplemental imaging at clinical discretion. However, patients are not routinely informed. Advocacy groups including Breast Cancer Now are actively pressing NHS England for the same notification standards now required by law in the US.

What to do if you have dense breasts

• If you are in the US and received a density notification, discuss it with your GP or screening provider. High density alone does not mean you will develop cancer — but it is a factor worth discussing, particularly if you have other risk factors.
• Ask whether supplemental screening is appropriate for you based on your overall risk profile.
• In the UK, you can ask your GP or breast screening unit about your density — especially if you have a family history or other risk factors.
• Continue attending NHS mammogram invitations. Mammography remains the best available screening tool even in dense tissue.
• Practice regular breast self-awareness (Touch–Look–Check) — especially important if you have dense breasts, as mammography may be less sensitive.

Supplemental screening options

• Ultrasound: can detect cancers not visible on mammogram in dense tissue. Widely available. Higher false-positive rate than mammography.
• Contrast-enhanced mammography (CEM): uses contrast dye to highlight areas of increased blood flow. Better sensitivity than standard mammography in dense tissue. Available in some NHS centres.
• MRI: the most sensitive supplemental screening tool, but expensive and reserved in the NHS for women at high hereditary risk (BRCA carriers and others). Accessible through private insurance for high-density patients in the US.
• Tomosynthesis (3D mammography): layered images that reduce the masking effect of dense tissue. Increasingly available in both countries.

Dense tissue is universal — access to imaging is not

Around 40% of women worldwide have dense breasts. The challenge this creates for mammographic detection is the same no matter where a woman lives. The difference is entirely in what happens next. In the UK, a woman receives an NHS mammogram. In the US, she now legally receives a written density notification. In low-income countries, she is almost certainly never offered a mammogram at all. The mobile screening units funded by donations to Breast Cancer Awareness deliver clinical breast examination and ultrasound to communities that have no other option. Your donation of £25 funds one of those screenings.